Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Nov 25, 2019 (7 years ago)

VCF Vaginal Contraceptive Foam

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Defective Delivery System: canister unit exhibiting propellant leakage or loss, rendering the product and canister unusable

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

VCF Vaginal Contraceptive Foam, a) can, 13 applications per can, Net wt. 0.6 oz (17g). NDC 52925-312-14, b) case pack with 36 cans in a nested container. Net wt 0.6 oz (17g) per can. NDC 52925-312-06, Distributed By: Apothecus Pharmaceutical Corp. Oyster Bay, NY 11771.

Affected NDCs 52925-0312-06 52925-0312-14

Compare with the code on your package — it is the most precise check available.

Recalling firm
Apothecus Pharmaceutical Corp.
NDC code
52925-312-14
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0623-2020 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Apothecus Pharmaceutical Corp.

All 2019 recalls

Other packaging defect recalls from 2019

All packaging defect recalls
Class III · Low risk

Clobetasol Propionate Foam

Defective delivery system; product is not foaming or is coming out as liquid.

Terminated Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-625-27 D-0619-2020
Class III · Low risk

Clobetasol Propionate Foam

Defective delivery system; product is not foaming or is coming out as liquid.

Terminated Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-608-27 D-0618-2020
Class II · Moderate risk

Estradiol Vaginal Inserts USP

Defective Delivery System: complaints for difficulty in pushing the plunger of the applicator.

Terminated Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-711-71 D-0156-2020
Class I · High risk

Natpara (parathyroid hormone)

Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing

Terminated Packaging defect Shire Human Genetic Therapies, Inc. D-0038-2020